Company intelligence / Profile preview

BlackThorn Therapeutics

San Francisco, California, United Statesbiospace.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

BlackThorn's lead drug BTRX-140 (formerly BTRX-335140), a selective KOR antagonist, advanced to Phase 2 clinical trials for major depressive disorder in January 2020. The Phase 2 proof-of-concept trial was designed to evaluate efficacy, safety, and tolerability in approximately 120 patients with major depressive disorder.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

BTRX-335140

Phase 2

Indications: Neuropsychiatric disorders

2 more assets in the full pipeline.

Request access →

Partnerships

Eli Lilly and Co.

Beyond the preview

Go deeper on BlackThorn Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BlackThorn Therapeutics.

Explore the full profile